Efficacy and Safety of Propiverine in Children with Overactive Bladder.
10.4111/kju.2012.53.4.275
- Author:
Woo Jung KIM
1
;
Dong Gi LEE
;
Sang Wook LEE
;
Yoon Kyung LEE
;
Jae Seung LEE
;
Kwan Hyun PARK
;
Minki BAEK
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. minki.baek@samsung.com
- Publication Type:Original Article
- Keywords:
Children;
Incontinence;
Overactive bladder;
Propiverine
- MeSH:
Benzilates;
Child;
Humans;
Muscarinic Antagonists;
Retrospective Studies;
Stress, Psychological;
Urinary Bladder;
Urinary Bladder, Overactive;
Urinary Incontinence, Urge
- From:Korean Journal of Urology
2012;53(4):275-279
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Antimuscarinic therapy remains one of the most common forms of therapy for overactive bladder (OAB) in children. However, few clinical studies on the outcomes of antimuscarinics in children with OAB have been published. Therefore, we evaluated the efficacy and safety of propiverine, which is frequently prescribed for the treatment of pediatric OAB. MATERIALS AND METHODS: We retrospectively reviewed children with OAB treated with propiverine within the past 5 years. The response rates were compared between the non-urge incontinence (non-UI) and urge incontinence (UI groups). The cumulative response rate by treatment duration was also compared between the two groups. RESULTS: Among a total of 68 children, 50 children (73.5%) experienced UI. The overall response rate was 86.8%. Functional bladder capacity after treatment was 150 ml, which represented an increase compared with the value (140 ml) before treatment. The voiding frequency per day decreased from 14.0 to 8.5 times. The overall response rate (88.0%) in the non-UI group was not significantly different from that seen in the UI group (83.3%; p>0.05). In non-UI children, the cumulative response rates were 36.0%, 54.0%, 68.0%, 74.0%, 76.0%, and 78.0% at 4, 8, 12, 16, 20, and 24 weeks, respectively. The cumulative response rates in the UI children were 11.1%, 33.3%, 44.4%, 50.0%, 50.0%, and 55.6%, respectively during the same respective time periods. Adverse effects were identified in only two (2.9%) patients, and neither case was severe. CONCLUSIONS: Propiverine is effective and well tolerated as a treatment for children suffering from OAB with or without UI.
